Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· April 3, 2026

Impact Analytics annonce un partenariat stratégique avec AllSaints

View original at globenewswire.com
Impact Analytics annonce un partenariat stratégique avec AllSaints LONDRES, 03 avr…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Brands like AllSaints are at a pivotal moment where speed, clarity and confidence in decision-making are essential

    60% confidence
  • One of AllSaints' four transformation pillars is to become a data-driven, AI-supported organization

    60% confidence
  • AllSaints team spends enormous time manually collecting and analyzing data, and this partnership will eliminate low-value repetitive tasks so merchandising managers can focus on understanding brand performance and making faster, better decisions

    60% confidence
  • With CortexEye, Monday reporting will be available by 8:00 AM detailed by department and team, enabling immediate business meetings and mid-day decision-making, compared to current process where data collection starts Sunday for Monday afternoon visibility

    60% confidence
  • Teams should be able to log in and immediately have a global view of what is happening across the brand worldwide and priorities to focus on, rather than having to search for this information

    60% confidence
  • This partnership aims to replace fragmented spreadsheets with a unified, AI-native platform and decision intelligence solution that strengthens merchandising team expertise, accelerates planning cycles and generates measurable impact on buying, pricing and inventory management decisions

    60% confidence
  • Impact Analytics is powered by over one million machine learning models and has been at the forefront of AI innovation for a decade, establishing new benchmarks in forecasting, planning and operational excellence

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com